• English
    X

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

     


    July 29, 2022

    Media Contacts:

    Deidre McCabe, Director of Communications, 410-767-3536

    Chase Cook, Deputy Director for Media Relations, 410-767-8649


    New COVID-19 vaccine available next week for Marylanders 18 and older

    Protein-based COVID-19 vaccine, produced by Novavax, a Maryland-based pharmaceutical company, is a two-dose primary series 


    Baltimore, MD—The Maryland Department of Health (MDH) announced all Marylanders 18 years old and older are now eligible to receive a primary series of the newly authorized Novavax COVID-19 vaccine.

     

    The Novavax COVID-19 vaccine is protein-based. Protein-based vaccines have been used for decades to combat diseases including hepatitis B and influenza. In a 30,000-participant clinical trial, the two-dose vaccine was 90% effective at preventing illness from COVID-19.

     

    On July 19, 2022, the U.S. Centers for Disease Control and Prevention (CDC) approved the Novavax vaccine for adult use. The Novavax vaccine will begin to arrive in Maryland as early as this week and should be available throughout the state beginning Monday, August 1, 2022.

     

    “We welcome yet another vaccine for Maryland adults to protect themselves against severe illness, hospitalization, and death from COVID-19,” said MDH Secretary Dennis R. Schrader. “For people who want a more traditional option, the Novavax vaccine is an ideal and exciting new opportunity for Marylanders to stay COVIDReady.”


    The U.S. government has secured 3.2 million Novavax vaccine doses, which are given as a two-dose primary vaccination series. Maryland has ordered more than 8,000 doses for distribution statewide to health care providers, pharmacists, and local health departments who requested the vaccine.


    On June 9, 2022, Governor Larry Hogan announced COVIDReady Maryland, the state’s long-term preparedness plan to maximize the tools and treatments available to keep people healthy and out of the hospital and maintain a state of readiness to respond to emerging variants and potential waves. 

     

    One of the best ways to stay COVIDReady is by vaccinating against COVID-19. Anyone can check their eligibility in seconds by using the “Are You Up-To-Date?” portal.

     

    On July 27, 2022, MDH updated its COVID-19 Vaccine provider bulletin to include the administration’s guidance for the Novavax COVID-19 vaccine in Maryland. 


    Marylanders can schedule a COVID-19 vaccination appointment by visiting covidvax.maryland.gov or calling the GoVAX Call Center at 1-855-MD-GOVAX. 


    For more information on COVID-19 resources, visit covidLINK.maryland.gov



    -###-​


    The Maryland Department of Health is dedicated to protecting and improving the health and safety of all Marylanders through disease prevention, access to care, quality management and community engagement. 

     

    Follow us at http://www.twitter.com/MDHealthDept and https://www.facebook.com/MDHealthDept